Positive trial for AlgoRx and Corgentech local anesthetic

ALGRX 3268 is a fast-acting local anesthetic and aimed at reducing pain associated with venipunctures and intravenous line placements.

Treatment with ALGRX 3268 demonstrated statistically significantly less pain upon needle insertion compared with the placebo group. The drug was also well tolerated and demonstrated no significant safety issues.

This trial was conducted at nine centers in the US in patients 3 to 18 years of age. A total of 535 patients were administered a placebo or the local anesthetic one to three minutes before having their procedures which required either venipuncture or intravenous line placement. The primary endpoint was a reduction in pain upon needle insertion.

“We are very pleased with the data announced today and believe that the results from these two phase III clinical trials demonstrate that ALGRX 3268 could be beneficial to patients by reducing local pain with a much faster onset of action than the drugs that are currently on the market,” stated Dr Ronald Burch, CEO of AlgoRx. “The data from these two trials will be included in a new drug application (NDA) for ALGRX 3268, which we expect to file with the FDA during 2006.”